Aravax to Communicate Results of its Phase 2 Clinical Trial of PVX108, a Novel immunotherapy for the Treatment of Peanut Allergy, at Major Scientific Meetings in November 2026

Data ReadoutPVX108Neutral

AI Analysis

Summary

Aravax announced it will present Phase 2 topline results for PVX108, a novel immunotherapy for peanut allergy treatment, at major scientific conferences in November 2026.

Clinical Trial Data

Phase

Phase 2

Outcome Details

topline results from Phase 2 study to be communicated at major scientific conferences

Importance:6/10

Sentiment:

0.00

immunotherapyfood allergypeanut allergyPhase 2data readout

Related Companies

$GBIO $AGY.L $ONT.L $UTHR

Read the original article

Published by GlobeNewswire Clinical Studies on October 5, 2026 8:00 AM

Read Original